38 u00b1 0 05 u00e5 d 5 19 u00b1 0 05 u00e5 d 4 87 u00b1 0 05 u00e5 d 3 72 u00b1 0 05 u00e5 and d 3 45 u00b1 0 05 u00e5 xxiii crystalline 1 2 4 3 trifluoro methyl phenyl piperazin 1 yl ethyl 2 3 dihydro 1h benzimidazol 2 one fumarate form ii dihydrate form characterized by a melting point of t fus onset 193 u00b1 5 u00b0 c which occurs during thermal analysis using dsc the dsc diagram is additionally characterised in that a further weakly endothermic signal can be observed at approx 157 u00b0 c particularly characteristic peaks in the x ray powder diffractogram of this compound are d 5 42 u00b1 0 05 u00e5 d 4 73 u00b1 0 05 u00e5 d 4 25 u00b1 0 05 u00e5 d 4 06 u00b1 0 05 u00e5 and d 3 72 u00b1 0 05 u00e5 xxiv crystalline 1 2 4 3 trifluoro methyl phenyl piperazin 1 yl ethyl 2 3 dihydro 1h benzimidazol 2 one glycolate form i hydrate form characterized by a melting point of t fus onset 139 u00b1 5 u00b0 c which occurs during thermal analysis using dsc the dsc diagram is additionally characterised in that two further weakly endothermic signals can be observed at approx 30 u00b0 c and 115 u00b0 c particularly characteristic peaks in the x ray powder diffractogram of this compound are d 3 96 u00b1 0 05 u00e5 d 4 48 u00b1 0 05 u00e5.